Aclarion Launches Initiative to Integrate AI-Powered Nociscan in Personal Injury and Workers Compensation Cases

Aclarion, Inc., a healthcare technology company specializing in chronic low back pain diagnosis, has announced a new initiative to integrate its AI-powered Nociscan technology into the personal injury and workers compensation sector. The program, launched in partnership with orthopedic surgeon Dr. Justin Kubeck, aims to develop a statewide network of providers in New Jersey who will utilize Nociscan to objectively evaluate chronic low back pain patients within these complex legal and medical systems.

Dr. Kubeck, founder of Ocean Pain and Spine in Toms River, NJ, will spearhead efforts to educate judges, lawyers, and healthcare professionals about the potential benefits of Nociscan in providing objective measurements for low back pain diagnoses. This initiative is particularly significant given the high stakes involved in personal injury and workers compensation claims related to neck and back injuries.

According to the press release, the average settlement for personal injury claims involving the neck and back in New Jersey is $918,967, while work-related accidents causing similar injuries have a national average settlement of $148,750. These figures underscore the financial implications for workers, employers, and insurance companies, highlighting the importance of accurate and objective diagnostic tools in determining appropriate treatments and compensation.

Nociscan, Aclarion's flagship product, uses Magnetic Resonance Spectroscopy (MRS) data from MRI machines to analyze chemical biomarkers associated with disc pain. The technology employs proprietary signal processing techniques and AI algorithms to indicate whether a disc may be a source of pain, potentially providing crucial insights for treatment decisions and legal proceedings.

Ryan Bond, Chief Strategy Officer of Aclarion, emphasized the company's plans to expand this initiative beyond New Jersey, stating, "Once established in New Jersey, we will target other markets throughout the United States to replicate the success of the NJ market." This expansion could significantly impact how chronic low back pain is evaluated and treated in personal injury and workers compensation cases nationwide.

The integration of Nociscan into these legal and medical processes could potentially streamline the evaluation of claims, provide more objective evidence for treatment recommendations, and influence settlement outcomes. For patients suffering from chronic low back pain due to work-related injuries or personal accidents, this technology may lead to more accurate diagnoses and appropriate treatment plans.

As the program develops, it will be crucial to monitor its effectiveness in improving patient outcomes, reducing litigation times, and potentially lowering costs associated with prolonged legal battles and inappropriate treatments. The success of this initiative could set a new standard for the use of AI and biomarker technology in medico-legal cases involving chronic pain.

Aclarion's move into the personal injury and workers compensation market represents a significant application of its technology beyond traditional clinical settings. If successful, this approach could not only benefit patients and healthcare providers but also have far-reaching implications for the legal and insurance industries involved in these types of cases.

For more information about Nociscan and Aclarion's technologies, interested parties can visit www.aclarion.com.